Daré Bioscience (DARE) Scheduled to Post Quarterly Earnings on Tuesday

Posted by William Tyler on May 8th, 2024

Daré Bioscience (NASDAQ:DARE – Get Free Report) will issue its quarterly earnings data after the market closes on Tuesday, May 14th. Analysts expect the company to announce earnings of ($0.06) per share for the quarter.

Daré Bioscience (NASDAQ:DARE – Get Free Report) last released its earnings results on Thursday, March 28th. The biotechnology company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.06. The firm had revenue of $1.81 million for the quarter, compared to the consensus estimate of $2.17 million. On average, analysts expect Daré Bioscience to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Daré Bioscience Stock Performance

DARE traded down $0.01 during trading on Wednesday, reaching $0.31. 27,221 shares of the company traded hands, compared to its average volume of 569,581. The firm has a fifty day simple moving average of $0.44 and a 200 day simple moving average of $0.38. Daré Bioscience has a 12-month low of $0.27 and a 12-month high of $1.06. The company has a market cap of $30.68 million, a P/E ratio of -0.91 and a beta of 1.31.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on the stock. Dawson James lowered shares of Daré Bioscience from a “buy” rating to a “neutral” rating in a report on Tuesday, January 30th. HC Wainwright reaffirmed a “buy” rating and set a $6.00 target price on shares of Daré Bioscience in a research report on Wednesday, May 1st. Finally, Brookline Capital Management lowered Daré Bioscience from a “buy” rating to a “hold” rating in a report on Wednesday, April 17th.

View Our Latest Stock Report on DARE

About Daré Bioscience

(Get Free Report)

Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.